Axxcess Wealth Management LLC Sells 5,823 Shares of Bristol-Myers Squibb (NYSE:BMY)

Axxcess Wealth Management LLC lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 7.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 68,530 shares of the biopharmaceutical company's stock after selling 5,823 shares during the period. Axxcess Wealth Management LLC's holdings in Bristol-Myers Squibb were worth $3,876,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Swedbank AB increased its stake in shares of Bristol-Myers Squibb by 0.9% in the third quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company's stock worth $162,440,000 after purchasing an additional 28,427 shares in the last quarter. United Bank increased its stake in shares of Bristol-Myers Squibb by 2.7% in the third quarter. United Bank now owns 17,322 shares of the biopharmaceutical company's stock worth $896,000 after purchasing an additional 456 shares in the last quarter. Natixis Advisors LLC boosted its position in shares of Bristol-Myers Squibb by 34.9% in the third quarter. Natixis Advisors LLC now owns 446,364 shares of the biopharmaceutical company's stock valued at $23,095,000 after acquiring an additional 115,361 shares during the period. Thrivent Financial for Lutherans boosted its position in shares of Bristol-Myers Squibb by 4.9% in the third quarter. Thrivent Financial for Lutherans now owns 116,801 shares of the biopharmaceutical company's stock valued at $6,044,000 after acquiring an additional 5,407 shares during the period. Finally, TrinityPoint Wealth LLC boosted its position in shares of Bristol-Myers Squibb by 8.7% in the third quarter. TrinityPoint Wealth LLC now owns 6,550 shares of the biopharmaceutical company's stock valued at $339,000 after acquiring an additional 522 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Remove Ads

Bristol-Myers Squibb Trading Up 1.1 %

Shares of BMY traded up $0.64 during mid-day trading on Friday, reaching $61.06. The company's stock had a trading volume of 25,864,960 shares, compared to its average volume of 12,180,118. The stock has a market cap of $123.92 billion, a PE ratio of -13.82, a P/E/G ratio of 2.07 and a beta of 0.43. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The company's fifty day moving average price is $58.17 and its two-hundred day moving average price is $55.89.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 4.06%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's payout ratio is -56.11%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on BMY shares. Bank of America restated a "neutral" rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Cantor Fitzgerald raised their price objective on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Wells Fargo & Company raised their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Truist Financial raised their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Finally, Citigroup lifted their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $57.86.

Insider Buying and Selling

In related news, EVP Samit Hirawat acquired 1,823 shares of Bristol-Myers Squibb stock in a transaction on Friday, February 14th. The shares were acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the transaction, the executive vice president now owns 63,932 shares in the company, valued at $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.09% of the stock is owned by insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.